Full text is available at the source.
Gut Microbiome Strategies for Enhancing ICI Delivery Across the BBB in Glioblastoma
Gut Microbiome Approaches to Improve Immune Therapy Delivery Across the Brain Barrier in Glioblastoma
AI simplified
Abstract
The median survival for glioblastoma is 14 months despite conventional treatments.
- Resistance to conventional therapies necessitates innovative approaches like immune checkpoint inhibitors targeting CTLA-4, PD-1, and PD-L1.
- Limited efficacy of immune checkpoint inhibitors in glioblastoma is associated with its immunosuppressive microenvironment and the blood-brain tumor barrier.
- Emerging evidence suggests that the gut microbiota may enhance T-cell function and immune modulation through the gut-brain axis in cancers.
- Gut-derived metabolites, such as short-chain fatty acids, may support immune responses and maintain blood-brain barrier integrity.
- Future glioblastoma research should focus on clinical trials and strategies like fecal microbiota transplantation and probiotics to improve immune checkpoint inhibitor efficacy.
AI simplified